Markets
Nia Warfield, Luke Kawa

S&P 500 matches longest winning streak since 2023 on strong megacap tech earnings

US stocks surged out of the gate thanks to stellar earnings reports from megacap giants after the close on Wednesday and were poised for another day of massive gains, but gave back about half their advance for seemingly no reason late in the session.

The S&P 500 and Russell 2000 gained 0.6%, while the the Nasdaq 100 outperformed with a rise of 1.1%.

That marks eight straight positive days for the benchmark US stock index, tying a streak last seen in November 2023.

Tech was the best-performing S&P 500 sector ETF by far, while investors exited defensive sectors like consumer staples and healthcare.

Microsoft shares were still flying high (helping prop up the S&P 500) after topping earnings expectations Wednesday. Now the tech giant is hiking the price of its Xbox Series X console by $100 in the US — blame “market conditions.”

Meta also beat expectations on the top and bottom lines, fueling a 4% rise.

These solid reports from two so-called AI hyperscalers rejuvenated the AI trade in a big way: Nvidia, notably, rose 2.5% on a wave of investor enthusiasm.

Some more bright spots:

Roblox gained 3% after the gaming giant topped Q1 estimates and said daily active users soared.

Kohl’s shares jumped nearly 8% after the retailer ousted its CEO, saying he made company vendor deals tied to personal connections.

CVS jumped after the pharmacy chain reported an earnings beat and raised its full-year guidance.

Meanwhile, Eli Lilly and Qualcomm were some of the worst performers on the day, despite both posting earnings beats. Speaking of…

Shares of pharma giant Moderna also slipped despite topping Wall Street estimates, as sales for its COVID-19 vaccine (its biggest revenue driver) have slowed.

GM shares shed all their premarket gains Thursday after the automaker issued full-year guidance that showed tariffs could cost it between $4 billion and $5 billion this year.

Robinhood Markets shares fell as analysts dug into its latest earnings results, which beat on the top and bottom lines, but investors weren’t thrilled with its EBITDA guidance. (Full disclosure: Sherwood Media is an editorially independent subsidiary of Robinhood Markets Inc.)

McDonald’s slipped nearly 2% after the Big Mac maker beat profit estimates, but missed on revenue and posted its worst same-store sales decline since 2020.

More Markets

See all Markets
markets
Jon Keegan

Meta shares rally as Jefferies says it’s a bargain relative to Mag 7 peers

Shares of Meta rallied over 5% today, as Jefferies analyst Brent Thill doubled down on his buy rating for the company, calling the stock a relative bargain compared to its Magnificent 7 peers. The analyst set a price target of $910, well above the $645 where the stock is trading today.

News out of Davos this week that Meta’s first models from its revamped AI teams are “very good” align with Thill’s argument that the company is well positioned to get back in the AI race with the “all-star model,” which is expected to be released in the first half of the year.

Recent cuts to its Reality Labs also signal that the company is focusing its spending where it matters. The Jefferies note also said the recent monetization of Threads via ads will help boost revenue.

Next week, Meta reports its fourth-quarter earnings, and Thill expects that even if Meta raises its 2026 capex outlook, investors won’t be spooked, as the company has been clear that spending may continue to be high.

Recent cuts to its Reality Labs also signal that the company is focusing its spending where it matters. The Jefferies note also said the recent monetization of Threads via ads will help boost revenue.

Next week, Meta reports its fourth-quarter earnings, and Thill expects that even if Meta raises its 2026 capex outlook, investors won’t be spooked, as the company has been clear that spending may continue to be high.

markets
Matt Phillips

Arista Networks rips higher amid jump in call buying

Arista Networks, a maker of switches and other networking equipment used in AI data centers, was on track for its best day of the new year on Thursday as options traders went bullish on the stock.

As of around 11 a.m. ET, there was nearly twice as much call buying in Arista than its 10-day moving average for a full day of activity. Buying call options to make leveraged bets on price increases has been a favorite trading tactic of retail traders in recent years.

Otherwise, there weren’t clear headlines tied to today’s outsized move, but the stock has been getting attention lately: in a note published earlier this month, Goldman Sachs analysts spotlighted Arista as a top tactical trade for earnings season, saying the shares — which they rate a “buy” — could rise 20% over the next year.

“ANET is well positioned amidst ongoing data center spending growth, where its position as a best of breed provider of networking equipment should advantage the company, particularly as data center networks become increasingly complex,” Goldman analysts wrote in the January 8 report.

And recent reports also say Microsoft — which accounted for 20% of Arista’s revenue in 2024, according to Goldman Sachs — is planning a massive expansion of its Wisconsin data center project.

Arista stock did get a lift following the release of solid US economic numbers at 8:30 a.m. that seemed fairly specific to Arista itself. (There was no similar bounce from competitors like Cisco or Hewlett-Packard.)

Microsoft receives preliminary approval for $13.3B data center expansion in Mount Pleasant - Milwaukee Business Journal

Microsoft receives preliminary approval for $13.3B data center expansion in Mount Pleasant - Milwaukee Business Journal

Otherwise, there weren’t clear headlines tied to today’s outsized move, but the stock has been getting attention lately: in a note published earlier this month, Goldman Sachs analysts spotlighted Arista as a top tactical trade for earnings season, saying the shares — which they rate a “buy” — could rise 20% over the next year.

“ANET is well positioned amidst ongoing data center spending growth, where its position as a best of breed provider of networking equipment should advantage the company, particularly as data center networks become increasingly complex,” Goldman analysts wrote in the January 8 report.

And recent reports also say Microsoft — which accounted for 20% of Arista’s revenue in 2024, according to Goldman Sachs — is planning a massive expansion of its Wisconsin data center project.

Arista stock did get a lift following the release of solid US economic numbers at 8:30 a.m. that seemed fairly specific to Arista itself. (There was no similar bounce from competitors like Cisco or Hewlett-Packard.)

markets
Luke Kawa

Investors just made a mammoth $133 billion flip from cash to stocks, per Goldman Sachs

It’s a dash from cash, with investors taking billions in dry powder and pouring that money into the stock market.

“We saw strong net flows into global equity funds last week, led by stronger inflows into US and EM equity funds (+$71 billion vs $2 billion in the previous week) — more than 35x-ed the flows,” wrote Goldman Sachs’ Gail Hafif, Brian Garrett, and Lee Coppersmith. “While equity flows increase, money market fund assets fell by $62 billion. This is the 3rd largest level in our dataset (!).”

Goldman cash to stocks flows

The trio is bullish on US stocks, seeing “the case for contained selloffs coupled with relief rallies as the most likely path forward in the near term.”

Luke Kawa
4h
Retail traders’ monthly appetite for stocks ascends to fresh record

“The current ‘new year’ momentum has been sustained and has now pushed retail activity to an all-time high on a rolling monthly basis,” according to JPMorgan.

BRITAIN-LONDON-FIREWORKS-NEW YEAR-CELEBRATION
markets
J. Edward Moreno

Moderna extends rally on positive cancer vaccine results

Moderna has more than doubled since it announced on Tuesday that its cancer vaccine reduced the risk of relapse or death for melanoma patients.

The five-year data from a Phase 2b trial showed that Moderna’s vaccine, when used with Merck’s blockbuster treatment Keytruda, reduced the risk of recurrence or death by 49% compared with Keytruda alone. The news gave investors hope that Moderna, which is best known for quickly developing a COVID-19 vaccine, may soon have another lucrative product in its portfolio.

Last week, Moderna said it expects to report total 2025 revenue of $1.9 billion, on the high end of its latest guidance of between $1.6 billion and $2 billion, amid better-than-expected vaccination rates. As demand for the COVID-19 vaccine, its sole revenue-generating product, has tanked, the company has aggressively cut costs and focused on expanding its portfolio.

The combination of positive announcements early in the year has made Moderna the second-best performer in the S&P 500 Index in 2026, behind newfound AI darling Sandisk.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.
©2026 Sherwood Media, LLC